These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 31766556

  • 1. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O.
    Medicina (Kaunas); 2019 Nov 21; 55(12):. PubMed ID: 31766556
    [Abstract] [Full Text] [Related]

  • 2. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
    Breunig C, Mueller BJ, Umansky L, Wahl K, Hoffmann K, Lehner F, Manns MP, Bantel H, Falk CS.
    Clin Cancer Res; 2014 May 01; 20(9):2410-23. PubMed ID: 24573550
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z, Giacobbi AS, Louandre C, Sauzay C, Mammeri Y, Galmiche A.
    Cancer Lett; 2017 Apr 28; 392():1-8. PubMed ID: 28161506
    [Abstract] [Full Text] [Related]

  • 5. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J, De la Rosa AJ, Docobo F, García-Carbonero R, Padillo FJ.
    Curr Cancer Drug Targets; 2013 Mar 28; 13(3):300-12. PubMed ID: 23016985
    [Abstract] [Full Text] [Related]

  • 6. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 7. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
    Huynh H, Soo KC, Chow PK, Tran E.
    Mol Cancer Ther; 2007 Jan 01; 6(1):138-46. PubMed ID: 17237274
    [Abstract] [Full Text] [Related]

  • 8. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C.
    Gut; 2018 Jul 01; 67(7):1328-1341. PubMed ID: 29275358
    [Abstract] [Full Text] [Related]

  • 9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 01; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 10. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.
    Cancer Discov; 2015 Apr 01; 5(4):358-67. PubMed ID: 25673644
    [Abstract] [Full Text] [Related]

  • 11. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 01; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 12. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 01; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 13. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
    Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.
    Eur J Cancer; 2017 Mar 01; 73():85-92. PubMed ID: 28169047
    [Abstract] [Full Text] [Related]

  • 14. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB.
    Eur J Med Chem; 2014 Jan 24; 72():170-205. PubMed ID: 24424304
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 16. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
    Kim S, Abou-Alfa GK.
    Clin Adv Hematol Oncol; 2014 Jan 15; 12(1):36-41. PubMed ID: 25000314
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 15; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 18. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ, Rizos H, Scolyer RA, Long GV.
    Eur J Cancer; 2016 Jul 15; 62():76-85. PubMed ID: 27232329
    [Abstract] [Full Text] [Related]

  • 19. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Jul 15; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 20. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.